Literature DB >> 15011787

Technology evaluation: Matuzumab, Merck KGaA.

Tracy Kim1.   

Abstract

Merck KGaA is developing matuzumab, a fully humanized epidermal growth factor receptor (EGFR)-specific monoclonal antibody, as a potential treatment for EGFR-bearing tumors. Matuzumab is currently undergoing phase II clinical trials for gastric, cervical, pancreatic and ovarian cancers.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15011787

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  5 in total

Review 1.  Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.

Authors:  J C Becker; C Muller-Tidow; H Serve; W Domschke; T Pohle
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 2.  ["Targeted Therapies" in NSCLC - present and future].

Authors:  Georg Pall; Wolfgang Hilbe
Journal:  Wien Med Wochenschr       Date:  2007

Review 3.  Accessing Intracellular Targets through Nanocarrier-Mediated Cytosolic Protein Delivery.

Authors:  Ritabrita Goswami; Taewon Jeon; Harini Nagaraj; Shumei Zhai; Vincent M Rotello
Journal:  Trends Pharmacol Sci       Date:  2020-09-02       Impact factor: 14.819

4.  Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab.

Authors:  Debora D Meira; Vitor H Almeida; Jânio S Mororó; Mauricio S Caetano; Isabel P Nóbrega; Delano Batista; Cinthya Sternberg; Carlos G Ferreira
Journal:  Mol Cancer       Date:  2011-12-20       Impact factor: 27.401

Review 5.  Strategies and methodologies for identifying molecular targets in sarcomas and other tumors.

Authors:  Vinod Ravi; Michael K K Wong
Journal:  Curr Treat Options Oncol       Date:  2005-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.